Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

When Should Guidelines Change? A Clarion Call for Evidence Regarding the Benefits and Risks of Screening for Colorectal Cancer at Earlier Ages.

Corley DA, Peek RM Jr.

Gastroenterology. 2018 Sep 4. pii: S0016-5085(18)34929-1. doi: 10.1053/j.gastro.2018.08.040. [Epub ahead of print] No abstract available.

PMID:
30193780
2.

Index colonoscopy-related risk factors for postcolonoscopy colorectal cancers.

Tollivoro TA, Jensen CD, Marks AR, Zhao WK, Schottinger JE, Quinn VP, Ghai NR, Zauber AG, Doubeni CA, Levin TR, Fireman B, Quesenberry CP, Corley DA.

Gastrointest Endosc. 2018 Aug 22. pii: S0016-5107(18)32981-X. doi: 10.1016/j.gie.2018.08.023. [Epub ahead of print]

PMID:
30144415
3.

Overdiagnosis in Colorectal Cancer Screening: Time to Acknowledge a Blind Spot.

Kalager M, Wieszczy P, Lansdorp-Vogelaar I, Corley DA, Bretthauer M, Kaminski MF.

Gastroenterology. 2018 Sep;155(3):592-595. doi: 10.1053/j.gastro.2018.07.037. Epub 2018 Aug 1. No abstract available.

PMID:
30076834
4.

Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large, Community-based Population.

Levin TR, Corley DA, Jensen CD, Schottinger JE, Quinn VP, Zauber AG, Lee JK, Zhao WK, Udaltsova N, Ghai NR, Lee AT, Quesenberry CP, Fireman BH, Doubeni CA.

Gastroenterology. 2018 Jul 19. pii: S0016-5085(18)34783-8. doi: 10.1053/j.gastro.2018.07.017. [Epub ahead of print]

PMID:
30031768
5.

Obesity and renal cell carcinoma risk by histologic subtype: A nested case-control study and meta-analysis.

Callahan CL, Hofmann JN, Corley DA, Zhao WK, Shuch B, Chow WH, Purdue MP.

Cancer Epidemiol. 2018 Jul 17;56:31-37. doi: 10.1016/j.canep.2018.07.002. [Epub ahead of print]

PMID:
30029068
6.

World Endoscopy Organization Consensus Statements on Post-Colonoscopy and Post-Imaging Colorectal Cancer.

Rutter MD, Beintaris I, Valori R, Chiu HM, Corley DA, Cuatrecasas M, Dekker E, Forsberg A, Gore-Booth J, Haug U, Kaminski MF, Matsuda T, Meijer GA, Morris E, Plumb AA, Rabeneck L, Robertson DJ, Schoen RE, Singh H, Tinmouth J, Young GP, Sanduleanu S.

Gastroenterology. 2018 Sep;155(3):909-925.e3. doi: 10.1053/j.gastro.2018.05.038. Epub 2018 Jun 27.

PMID:
29958856
7.

Health care improvement and survivorship priorities of colorectal cancer survivors: findings from the PORTAL colorectal cancer cohort survey.

McMullen C, Bulkley J, Corley DA, Madrid S, Davis AQ, Hesselbrock R, Kurtilla F, Anderson CK, Arterburn D, Somkin CP, Pawloski PA, Ghai NR, Feigelson HS.

Support Care Cancer. 2018 Jun 12. doi: 10.1007/s00520-018-4299-6. [Epub ahead of print]

PMID:
29948396
8.

Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium.

Wang Z, Shaheen NJ, Whiteman DC, Anderson LA, Vaughan TL, Corley DA, El-Serag HB, Rubenstein JH, Thrift AP.

Am J Gastroenterol. 2018 Aug;113(8):1148-1155. doi: 10.1038/s41395-018-0070-3. Epub 2018 Jun 8.

PMID:
29880962
9.

Timely follow-up of positive cancer screening results: A systematic review and recommendations from the PROSPR Consortium.

Doubeni CA, Gabler NB, Wheeler CM, McCarthy AM, Castle PE, Halm EA, Schnall MD, Skinner CS, Tosteson ANA, Weaver DL, Vachani A, Mehta SJ, Rendle KA, Fedewa SA, Corley DA, Armstrong K.

CA Cancer J Clin. 2018 May;68(3):199-216. doi: 10.3322/caac.21452. Epub 2018 Mar 30. Review.

10.

Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus.

Dong J, Levine DM, Buas MF, Zhang R, Onstad L, Fitzgerald RC; Stomach and Oesophageal Cancer Study (SOCS) Consortium, Corley DA, Shaheen NJ, Lagergren J, Hardie LJ, Reid BJ, Iyer PG, Risch HA, Caldas C, Caldas I, Pharoah PD, Liu G, Gammon MD, Chow WH, Bernstein L, Bird NC, Ye W, Wu AH, Anderson LA, MacGregor S, Whiteman DC, Vaughan TL, Thrift AP.

Clin Gastroenterol Hepatol. 2018 Mar 15. pii: S1542-3565(18)30262-3. doi: 10.1016/j.cgh.2018.03.007. [Epub ahead of print]

11.

Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States.

Singal AG, Corley DA, Kamineni A, Garcia M, Zheng Y, Doria-Rose PV, Quinn VP, Jensen CD, Chubak J, Tiro J, Doubeni CA, Ghai NR, Skinner CS, Wernli K, Halm EA.

Am J Gastroenterol. 2018 May;113(5):746-754. doi: 10.1038/s41395-018-0023-x. Epub 2018 Feb 27.

PMID:
29487413
12.

Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants.

Dong J, Buas MF, Gharahkhani P, Kendall BJ, Onstad L, Zhao S, Anderson LA, Wu AH, Ye W, Bird NC, Bernstein L, Chow WH, Gammon MD, Liu G, Caldas C, Pharoah PD, Risch HA, Iyer PG, Reid BJ, Hardie LJ, Lagergren J, Shaheen NJ, Corley DA, Fitzgerald RC; Stomach and Oesophageal Cancer Study (SOCS) consortium, Whiteman DC, Vaughan TL, Thrift AP.

Gastroenterology. 2018 Apr;154(5):1273-1281.e3. doi: 10.1053/j.gastro.2017.12.003. Epub 2017 Dec 13.

PMID:
29247777
13.

Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study.

Rutter CM, Kim JJ, Meester RGS, Sprague BL, Burger EA, Zauber AG, Ergun MA, Campos NG, Doubeni CA, Trentham-Dietz A, Sy S, Alagoz O, Stout N, Lansdorp-Vogelaar I, Corley DA, Tosteson ANA.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):158-164. doi: 10.1158/1055-9965.EPI-17-0378. Epub 2017 Nov 17.

PMID:
29150480
14.

The 75th Diamond Anniversary of Gastroenterology: 1943-2018.

Peek RM, Corley DA.

Gastroenterology. 2018 Jan;154(1):1-5. doi: 10.1053/j.gastro.2017.10.019. Epub 2017 Nov 9. No abstract available.

PMID:
29128318
15.

Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests: A Systematic Review.

Selby K, Baumgartner C, Levin TR, Doubeni CA, Zauber AG, Schottinger J, Jensen CD, Lee JK, Corley DA.

Ann Intern Med. 2017 Oct 17;167(8):565-575. doi: 10.7326/M17-1361. Epub 2017 Oct 10. Review.

PMID:
29049756
16.

Accurate Identification of Colonoscopy Quality and Polyp Findings Using Natural Language Processing.

Lee JK, Jensen CD, Levin TR, Zauber AG, Doubeni CA, Zhao WK, Corley DA.

J Clin Gastroenterol. 2017 Sep 12. doi: 10.1097/MCG.0000000000000929. [Epub ahead of print]

PMID:
28906424
17.

Dietary sugar/starches intake and Barrett's esophagus: a pooled analysis.

Li N, Petrick JL, Steck SE, Bradshaw PT, McClain KM, Niehoff NM, Engel LS, Shaheen NJ, Corley DA, Vaughan TL, Gammon MD.

Eur J Epidemiol. 2017 Nov;32(11):1007-1017. doi: 10.1007/s10654-017-0301-8. Epub 2017 Sep 1.

PMID:
28864851
18.

Diagnosis and predictors of sessile serrated adenoma after educational training in a large, community-based, integrated healthcare setting.

Li D, Woolfrey J, Jiang SF, Jensen CD, Zhao WK, Kakar S, Santamaria M, Rumore G, Armstrong MA, Postlethwaite D, Corley DA, Levin TR.

Gastrointest Endosc. 2018 Mar;87(3):755-765.e1. doi: 10.1016/j.gie.2017.08.012. Epub 2017 Aug 24.

PMID:
28843582
19.

Impact of adenoma detection on the benefit of faecal testing vs. colonoscopy for colorectal cancer.

Meester RGS, Doubeni CA, Zauber AG, van Ballegooijen M, Corley DA, Lansdorp-Vogelaar I.

Int J Cancer. 2017 Dec 1;141(11):2359-2367. doi: 10.1002/ijc.30933. Epub 2017 Aug 31.

PMID:
28815573
20.

Time to Diagnostic Testing After a Positive Colorectal Cancer Screening Test.

Doubeni CA, Corley DA, Levin TR.

JAMA. 2017 Aug 1;318(5):483. doi: 10.1001/jama.2017.9312. No abstract available.

PMID:
28763543
21.

The Reply.

Lo Re V 3rd, Carbonari DM, Lewis JD, Roy JA, Corley DA.

Am J Med. 2017 Aug;130(8):e369. doi: 10.1016/j.amjmed.2017.03.062. No abstract available.

PMID:
28734384
22.

Primary care visit use after positive fecal immunochemical test for colorectal cancer screening.

Hillyer GC, Jensen CD, Zhao WK, Neugut AI, Lebwohl B, Tiro JA, Kushi LH, Corley DA.

Cancer. 2017 Oct 1;123(19):3744-3753. doi: 10.1002/cncr.30809. Epub 2017 Jun 16.

PMID:
28621809
23.

The Troublesome Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma.

Schneider JL, Corley DA.

Gastrointest Endosc Clin N Am. 2017 Jul;27(3):353-364. doi: 10.1016/j.giec.2017.03.002. Review.

PMID:
28577761
24.

Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status.

Gowda C, Newcomb CW, Liu Q, Carbonari DM, Lewis JD, Forde KA, Goldberg DS, Reddy KR, Roy JA, Marks AR, Schneider JL, Kostman JR, Tate JP, Lim JK, Justice AC, Goetz MB, Corley DA, Lo Re V.

Open Forum Infect Dis. 2017 Jan 28;4(2):ofx012. doi: 10.1093/ofid/ofx012. eCollection 2017 Spring.

25.

Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis.

Corley DA, Jensen CD, Quinn VP, Doubeni CA, Zauber AG, Lee JK, Schottinger JE, Marks AR, Zhao WK, Ghai NR, Lee AT, Contreras R, Quesenberry CP, Fireman BH, Levin TR.

JAMA. 2017 Apr 25;317(16):1631-1641. doi: 10.1001/jama.2017.3634.

PMID:
28444278
26.

Colorectal Cancer Screening Initiation After Age 50 Years in an Organized Program.

Fedewa SA, Corley DA, Jensen CD, Zhao W, Goodman M, Jemal A, Ward KC, Levin TR, Doubeni CA.

Am J Prev Med. 2017 Sep;53(3):335-344. doi: 10.1016/j.amepre.2017.02.018. Epub 2017 Apr 17.

27.

Racial/ethnic differences in obesity and comorbidities between safety-net- and non safety-net integrated health systems.

Balasubramanian BA, Garcia MP, Corley DA, Doubeni CA, Haas JS, Kamineni A, Quinn VP, Wernli K, Zheng Y, Skinner CS.

Medicine (Baltimore). 2017 Mar;96(11):e6326. doi: 10.1097/MD.0000000000006326.

28.

Oral bisphosphonates and colorectal cancer.

Vogtmann E, Corley DA, Almers LM, Cardwell CR, Murray LJ, Abnet CC.

Sci Rep. 2017 Mar 10;7:44177. doi: 10.1038/srep44177.

29.

Optimizing patient-reported outcome and risk factor reporting from cancer survivors: a randomized trial of four different survey methods among colorectal cancer survivors.

Feigelson HS, McMullen CK, Madrid S, Sterrett AT, Powers JD, Blum-Barnett E, Pawloski PA, Ziegenfuss JY, Quinn VP, Arterburn DE, Corley DA.

J Cancer Surviv. 2017 Jun;11(3):393-400. doi: 10.1007/s11764-017-0596-1. Epub 2017 Jan 13.

30.

Fecal Immunochemical Test (FIT) for Colon Cancer Screening: Variable Performance with Ambient Temperature.

Doubeni CA, Jensen CD, Fedewa SA, Quinn VP, Zauber AG, Schottinger JE, Corley DA, Levin TR.

J Am Board Fam Med. 2016 Nov 12;29(6):672-681. doi: 10.3122/jabfm.2016.06.160060.

31.

Cancer incidence and mortality risks in a large US Barrett's oesophagus cohort.

Cook MB, Coburn SB, Lam JR, Taylor PR, Schneider JL, Corley DA.

Gut. 2018 Mar;67(3):418-529. doi: 10.1136/gutjnl-2016-312223. Epub 2017 Jan 4.

PMID:
28053055
32.

Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue.

Levin TR, Corley DA, Jensen CD, Marks AR, Zhao WK, Zebrowski AM, Quinn VP, Browne LW, Taylor WR, Ahlquist DA, Lidgard GP, Berger BM.

Dig Dis Sci. 2017 Mar;62(3):678-688. doi: 10.1007/s10620-016-4433-6. Epub 2017 Jan 2.

PMID:
28044229
33.

Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency.

Lam JR, Schneider JL, Quesenberry CP, Corley DA.

Gastroenterology. 2017 Mar;152(4):821-829.e1. doi: 10.1053/j.gastro.2016.11.023. Epub 2016 Nov 24.

PMID:
27890768
34.

Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.

Thrift AP, Anderson LA, Murray LJ, Cook MB, Shaheen NJ, Rubenstein JH, El-Serag HB, Vaughan TL, Schneider JL, Whiteman DC, Corley DA.

Am J Gastroenterol. 2016 Nov;111(11):1528-1535. doi: 10.1038/ajg.2016.348. Epub 2016 Aug 30.

35.

Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study.

Doubeni CA, Corley DA, Quinn VP, Jensen CD, Zauber AG, Goodman M, Johnson JR, Mehta SJ, Becerra TA, Zhao WK, Schottinger J, Doria-Rose VP, Levin TR, Weiss NS, Fletcher RH.

Gut. 2018 Feb;67(2):291-298. doi: 10.1136/gutjnl-2016-312712. Epub 2016 Oct 12.

36.

Human papillomavirus vaccination and subsequent cervical cancer screening in a large integrated healthcare system.

Chao C, Silverberg MJ, Becerra TA, Corley DA, Jensen CD, Chen Q, Quinn VP.

Am J Obstet Gynecol. 2017 Feb;216(2):151.e1-151.e9. doi: 10.1016/j.ajog.2016.10.006. Epub 2016 Oct 14.

37.

Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System.

Mehta SJ, Jensen CD, Quinn VP, Schottinger JE, Zauber AG, Meester R, Laiyemo AO, Fedewa S, Goodman M, Fletcher RH, Levin TR, Corley DA, Doubeni CA.

J Gen Intern Med. 2016 Nov;31(11):1323-1330. doi: 10.1007/s11606-016-3792-1. Epub 2016 Jul 13.

38.

Endoscopist fatigue estimates and colonoscopic adenoma detection in a large community-based setting.

Lee A, Jensen CD, Marks AR, Zhao WK, Doubeni CA, Zauber AG, Quinn VP, Levin TR, Corley DA.

Gastrointest Endosc. 2017 Mar;85(3):601-610.e2. doi: 10.1016/j.gie.2016.09.033. Epub 2016 Oct 1.

39.

Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis.

Gharahkhani P, Fitzgerald RC, Vaughan TL, Palles C, Gockel I, Tomlinson I, Buas MF, May A, Gerges C, Anders M, Becker J, Kreuser N, Noder T, Venerito M, Veits L, Schmidt T, Manner H, Schmidt C, Hess T, Böhmer AC, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Hackelsberger A, Mayershofer R, Pech O, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM; Barrett's and Esophageal Adenocarcinoma Consortium (BEACON); Esophageal Adenocarcinoma GenEtics Consortium (EAGLE); Wellcome Trust Case Control Consortium 2 (WTCCC2), Attwood S, Barr H, Chegwidden L, de Caestecker J, Harrison R, Love SB, MacDonald D, Moayyedi P, Prenen H, Watson RGP, Iyer PG, Anderson LA, Bernstein L, Chow WH, Hardie LJ, Lagergren J, Liu G, Risch HA, Wu AH, Ye W, Bird NC, Shaheen NJ, Gammon MD, Corley DA, Caldas C, Moebus S, Knapp M, Peters WHM, Neuhaus H, Rösch T, Ell C, MacGregor S, Pharoah P, Whiteman DC, Jankowski J, Schumacher J.

Lancet Oncol. 2016 Oct;17(10):1363-1373. doi: 10.1016/S1470-2045(16)30240-6. Epub 2016 Aug 12.

40.

Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma.

Buas MF, He Q, Johnson LG, Onstad L, Levine DM, Thrift AP, Gharahkhani P, Palles C, Lagergren J, Fitzgerald RC, Ye W, Caldas C, Bird NC, Shaheen NJ, Bernstein L, Gammon MD, Wu AH, Hardie LJ, Pharoah PD, Liu G, Iyer P, Corley DA, Risch HA, Chow WH, Prenen H, Chegwidden L, Love S, Attwood S, Moayyedi P, MacDonald D, Harrison R, Watson P, Barr H, deCaestecker J, Tomlinson I, Jankowski J, Whiteman DC, MacGregor S, Vaughan TL, Madeleine MM.

Gut. 2017 Oct;66(10):1739-1747. doi: 10.1136/gutjnl-2016-311622. Epub 2016 Aug 2.

41.

Leukocyte telomere length in relation to the risk of Barrett's esophagus and esophageal adenocarcinoma.

Wennerström EC, Risques RA, Prunkard D, Giffen C, Corley DA, Murray LJ, Whiteman DC, Wu AH, Bernstein L, Ye W, Chow WH, Vaughan TL, Liao LM.

Cancer Med. 2016 Sep;5(9):2657-65. doi: 10.1002/cam4.810. Epub 2016 Jul 6.

42.

Influence of Age and Comorbidity on Colorectal Cancer Screening in the Elderly.

Klabunde CN, Zheng Y, Quinn VP, Beaber EF, Rutter CM, Halm EA, Chubak J, Doubeni CA, Haas JS, Kamineni A, Schapira MM, Vacek PM, Garcia MP, Corley DA; PROSPR consortium.

Am J Prev Med. 2016 Sep;51(3):e67-75. doi: 10.1016/j.amepre.2016.04.018. Epub 2016 Jun 22.

43.

Association Between Primary Care Visits and Colorectal Cancer Screening Outcomes in the Era of Population Health Outreach.

Halm EA, Beaber EF, McLerran D, Chubak J, Corley DA, Rutter CM, Doubeni CA, Haas JS, Balasubramanian BA.

J Gen Intern Med. 2016 Oct;31(10):1190-7. doi: 10.1007/s11606-016-3760-9. Epub 2016 Jun 8.

44.

Inverse Association Between Gluteofemoral Obesity and Risk of Barrett's Esophagus in a Pooled Analysis.

Kendall BJ, Rubenstein JH, Cook MB, Vaughan TL, Anderson LA, Murray LJ, Shaheen NJ, Corley DA, Chandar AK, Li L, Greer KB, Chak A, El-Serag HB, Whiteman DC, Thrift AP.

Clin Gastroenterol Hepatol. 2016 Oct;14(10):1412-1419.e3. doi: 10.1016/j.cgh.2016.05.032. Epub 2016 Jun 2.

45.

The Dawning of a New Editorial Board for Gastroenterology.

Corley DA, Peek RM Jr.

Gastroenterology. 2016 Jul;151(1):4-8. doi: 10.1053/j.gastro.2016.05.008. Epub 2016 May 20. No abstract available.

PMID:
27215655
46.

Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test.

Meester RG, Zauber AG, Doubeni CA, Jensen CD, Quinn VP, Helfand M, Dominitz JA, Levin TR, Corley DA, Lansdorp-Vogelaar I.

Clin Gastroenterol Hepatol. 2016 Oct;14(10):1445-1451.e8. doi: 10.1016/j.cgh.2016.05.017. Epub 2016 May 19. Erratum in: Clin Gastroenterol Hepatol. 2018 May;16(5):787. Clin Gastroenterol Hepatol. 2018 Aug;16(8):1365.

47.

Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity.

McCarthy AM, Kim JJ, Beaber EF, Zheng Y, Burnett-Hartman A, Chubak J, Ghai NR, McLerran D, Breen N, Conant EF, Geller BM, Green BB, Klabunde CN, Inrig S, Skinner CS, Quinn VP, Haas JS, Schnall M, Rutter CM, Barlow WE, Corley DA, Armstrong K, Doubeni CA; PROSPR consortium.

Am J Prev Med. 2016 Oct;51(4):507-12. doi: 10.1016/j.amepre.2016.03.017. Epub 2016 Apr 28.

48.

Reducing Variation in the "Standard of Care" for Cancer Screening: Recommendations From the PROSPR Consortium.

Corley DA, Haas JS, Kobrin S.

JAMA. 2016 May 17;315(19):2067-8. doi: 10.1001/jama.2016.3067. No abstract available.

49.

Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems.

Burnett-Hartman AN, Mehta SJ, Zheng Y, Ghai NR, McLerran DF, Chubak J, Quinn VP, Skinner CS, Corley DA, Inadomi JM, Doubeni CA; PROSPR Consortium.

Am J Prev Med. 2016 Oct;51(4):e107-15. doi: 10.1016/j.amepre.2016.02.025. Epub 2016 Apr 1.

50.

Colorectal Cancer Health Disparities and the Role of US Law and Health Policy.

Doubeni CA, Corley DA, Zauber AG.

Gastroenterology. 2016 May;150(5):1052-1055. doi: 10.1053/j.gastro.2016.03.012. Epub 2016 Mar 24. No abstract available.

Supplemental Content

Loading ...
Support Center